drugset / Trial / NCT05871541
A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The goal of this clinical trial is to assess the safety and immunogenicity of a self-replicating (sr) RNA-based vaccine, JCXH-105, in the prevention of Shingles (Herpes Zoster) Participant will be randomized to receive either JCXH-105 or Shingrix.
Timeline
- Start
- 2023-05-26
- Primary completion
- 2024-03-25
- Completion
- 2024-03-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JCXH-105 | Other / unclassified | — | Intramuscular |
| Comparator | VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E | Vaccine | — | Intramuscular |